Parmar Chetan, Appel Simone, Lee Lyndcie, Ribeiro Rui, Sakran Nasser, Pouwels Sjaak
Department of Surgery, Whittington Health NHS Trust, London, N19 5NF, UK.
Medical School, University College London, London, UK.
Obes Surg. 2022 Dec;32(12):3992-4006. doi: 10.1007/s11695-022-06321-4. Epub 2022 Oct 22.
The prevalence of obesity in patients with type 1 diabetes mellitus (T1DM) has been increasing. Metabolic bariatric surgery (MBS) has proven to be effective in treating patients with T2DM. However, evidence for the benefit of the procedure for patients with T1DM is still limited, particularly in terms of glycemic control, demonstrating the need for a systematic review investigating this.
A systematic review was performed in accordance with the PRISMA guidelines. Outcome measures such as weight loss, remission of comorbidities, pre- and post-intervention insulin requirements, and HbA1c levels were extracted.
Thirty studies were included with a total of 706 patients (F = 524, M = 74, N/A = 60). The mean age was 40.01 years. The mean weight and body mass index (BMI) were 112.76 kg and 40.88 kg/m (24-58.9) respectively. The common procedure performed was RYGB (n = 497 (70.4%)), followed by SG (n = 131 (18.6%)). The mean decrease of insulin requirements was 92.3 IU/day (36.2-174) preoperatively to a mean of 35.8 IU/day (5-75) post-operatively. No significant trend was found for changes in HbA1c levels. The main side effects were episodes of hypoglycemia and diabetic ketoacidosis (DKA); there was no mortality. The mean %EWL was 74.57% (60-90.5%) at ≥ 6 follow-up months. Reductions in comorbidities such as hypertension and cardiovascular disease (CVD) were recorded in multiple studies.
Patients with obesity and T1DM can expect significant weight loss, potential resolution of comorbidities, and reduction of insulin requirements, but it does not usually result in improved glycemic control. Based on current review, best choice of bariatric surgery in such patients cannot yet be established.
1型糖尿病(T1DM)患者的肥胖患病率一直在上升。代谢性减肥手术(MBS)已被证明对治疗2型糖尿病(T2DM)患者有效。然而,该手术对T1DM患者益处的证据仍然有限,特别是在血糖控制方面,这表明需要进行系统评价来研究这一问题。
按照PRISMA指南进行系统评价。提取了体重减轻、合并症缓解、干预前后胰岛素需求量以及糖化血红蛋白(HbA1c)水平等结局指标。
纳入30项研究,共706例患者(女性=524例,男性=74例,未提及性别=60例)。平均年龄为40.01岁。平均体重和体重指数(BMI)分别为112.76 kg和40.88 kg/m²(24-58.9)。最常进行的手术是胃旁路术(RYGB,n=497例(70.4%)),其次是袖状胃切除术(SG,n=131例(18.6%))。胰岛素需求量术前平均减少92.3 IU/天(36.2-174),术后平均减少至35.8 IU/天(5-75)。未发现HbA1c水平变化的显著趋势。主要副作用是低血糖发作和糖尿病酮症酸中毒(DKA);无死亡病例。在≥6个月的随访中,平均体重减轻百分比(%EWL)为74.57%(60-90.5%)。多项研究记录了高血压和心血管疾病(CVD)等合并症的减少情况。
肥胖的T1DM患者有望显著减轻体重,合并症可能得到缓解,胰岛素需求量减少,但通常不会改善血糖控制。基于目前的评价,此类患者减肥手术的最佳选择尚未确定。